Emerging biotherapies for Sjögren's syndrome

Bibliography

• Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31
   PubMed Web of Science ®Google Scholar
• Youinou P. B cell conducts the lymphocyte orchestra. J Autoimmun 2007;28:143-51
   PubMed Web of Science ®Google Scholar
• Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 2004;164:1275-84
   PubMed Web of Science ®Google Scholar
• Delaleu N, Jonsson R, Koller MM. Sjögren's syndrome. Eur J Oral Sci 2005;113:101-13
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5
   PubMedGoogle Scholar
• Tzioufas AG, Voulgarelis M. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007;21:989-1010
   PubMed Web of Science ®Google Scholar
• Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:249-69
   PubMed Web of Science ®Google Scholar
• Bendaoud B, Pennec YL, Lelong A, IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome. J Autoimmun 1991;4:177-84
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren's Syndrome. Arthritis Rheum 1999;42:1765-72
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Moutsopoulos HM, Clasification criteria for Sjögren's syndrome. A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-58
   PubMed Web of Science ®Google Scholar
• Binard A, Le Pottier L, Devauchelle-Pensec V, Is the blood B-cell subset profile diagnostic for Sjögren's syndrome. Ann Rheum Dis 2009;68:1447-52
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74
   PubMed Web of Science ®Google Scholar
• Mount GR, Gilliland WR. Emerging biological therapies in systemic lupus erythematosus. Clin Pharmacol Ther 2008;83:167-71
   PubMed Web of Science ®Google Scholar
• Youinou P, Taher TE, Pers JO, B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum 2009;60:1873-80
   PubMed Web of Science ®Google Scholar
• Mitsias DI, Tzioufas AG, Veiopoulou C, The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 2002;128:562-8
   PubMed Web of Science ®Google Scholar
• Szodoray P, Alex P, Brun JG, Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004;59:592-9
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjögren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs 2000;9:2007-16
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96
   PubMed Web of Science ®Google Scholar
• Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009;18:690-7
   PubMed Web of Science ®Google Scholar
• Zhu Z, Stevenson D, Schechter JE, TNF inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea 2003;22:343-51
   PubMed Web of Science ®Google Scholar
• Sisto M, D'Amore M, Caprio S, TNF inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann NY Acad Sci 2009;1171:407-14
   PubMed Web of Science ®Google Scholar
• Batten M, Fletcher C, Ng LG, TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-22
   PubMed Web of Science ®Google Scholar
• Alsaleh G, Messer L, Semaan N, BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007;56:3202-14
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum 2002;46:3301-3
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's Syndrome. Arthritis Rheum 2004;50:1270-6
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T, Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95
   PubMed Web of Science ®Google Scholar
• Youinou P, Daridon C, Steinfeld S, Pers Jo. A case for B cells in the pathogenesis of Sjögren's syndrome. Curr Trends Immunol 2007;8:19-25
   Google Scholar
• Harris DP, Haynes L, Sayles PC, Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82
   PubMed Web of Science ®Google Scholar
• Harvey BP, Quan TE, Rudenga BJ, Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors. J Immunol 2008;181:4043-51
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-5
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Cook MC. The molecular basis of lymphoid architecture and B cell responses: implications for immunodeficiency and immunopathology. Curr Mol Med 2001;1:689-725
   PubMedGoogle Scholar
• Le Pottier L, Devauchelle V, Fautrel A, Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009;15:3540-7
   Web of Science ®Google Scholar
• Daridon C, Guerrier T, Devauchelle V, Polarization of B effector cells in Sjögren's syndrome. Autoimmun Rev 2007;6:427-31
   PubMed Web of Science ®Google Scholar
• Pers JO, Le Pottier L, Devauchelle V, B lymphocytes in Sjögren's syndrome. Rev Med Interne 2008;29:1000-6
   PubMed Web of Science ®Google Scholar
• Hansen A, Odendahl M, Reiter K, Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2160-71
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, de Wilde P, van Damme P, Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004;31:96-101
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, Etanercept in Sjögren's syndrome. Arthritis Rheum 2004;50:2240-5
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Salaffi F, De Vita S, IFN alpha2 increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-choloroquine. Clin Exp Rheumatol 1996;14:367-71
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-62
   PubMed Web of Science ®Google Scholar
• Ship JA, Fox PC, Michalek JE, Treatment of primary Sjögren's syndrome with low-dose natural human IFN-alpha administered by the oral mucosal route: a phase II clinical trial. J Interferon Cytokine Res 1999;19:943-51
   PubMed Web of Science ®Google Scholar
• Khurshudian AV. A pilot study to test the efficacy of oral administration of IFN-alpha lozenges to patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:38-44
   PubMed Web of Science ®Google Scholar
• Cummins MJ, Papas A, Kammer GM, Treatment of primary Sjögren's syndrome with low-dose human IFN-alpha administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93
   PubMed Web of Science ®Google Scholar
• Yamada S, Mori K, Matsuo K, IFN-alpha treatment for Sjögren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 2005;76:576-8
   PubMed Web of Science ®Google Scholar
• Engel P, Nojima Y, Rothstein D, The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J Immunol 1993;150:4719-32
   PubMed Web of Science ®Google Scholar
• Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005;88:1-50
   PubMed Web of Science ®Google Scholar
• Sato S, Miller AS, Inaoki M, CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-62
   PubMed Web of Science ®Google Scholar
• O'Keefe TL, Williams GT, Batista FD, Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999;189:1307-13
   PubMed Web of Science ®Google Scholar
• Einfeld DA, Brown JP, Valentine MA, Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7
   PubMed Web of Science ®Google Scholar
• Valentine MA, Meier KE, Rossie S, Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by PKC. J Biol Chem 1989;264:11282-7
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33
   PubMed Web of Science ®Google Scholar
• Tedder TF, Boyd AW, Freedman AS, The B cell molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4
   PubMedGoogle Scholar
• Press OW, Appelbaum F, Ledbetter JA, Monoclonal antibody 1F5 serotherapy of human B cell lymphomas. Blood 1987;69:584-91
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Youinou P. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 2006;6:943-9
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8:R129
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Dreyling M, Rohatiner A, Rationale for consolidation to improve progression-free survival in patients with NHL: a review of the evidence. Oncologist 2009;14 (Suppl 2):17-29
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Looney RJ, Deodhar A, Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74
   PubMed Web of Science ®Google Scholar
• Semac I, Palomba C, Kulangara K, Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003;63:534-40
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK, Rituximab treatment in patients with primary Sjögren's syndrome. Arthritis Rheum 2005;52:2740-50
   PubMed Web of Science ®Google Scholar
• Meijer JM, Pijpe J, Vissink A, Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009;68:284-5
   PubMed Web of Science ®Google Scholar
• Pijpe J, Meijer JM, Bootsma H, Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009;60:3251-6
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Pennec Y, Morvan J, Improvement of Sjögren's Syndrome after two infusions of rituximab. Arthritis Rheum 2007;57:310-7
   PubMed Web of Science ®Google Scholar
• Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics 2007;1:311-9
   PubMedGoogle Scholar
• Pers JO, Devauchelle V, Daridon C, BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-77
   PubMed Web of Science ®Google Scholar
• Daridon C, Devauchelle V, Hutin P, Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007;56:1134-44
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
   PubMed Web of Science ®Google Scholar
• Seror R, Sordet C, Guillevin L, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7
   PubMed Web of Science ®Google Scholar
• Galarza C, Valencia D, Tobón GJ, Should Rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008;34:124-8
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomized, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4
   PubMed Web of Science ®Google Scholar
• Shih WJ, Ghesani N, Hongming Z, F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002;27:142-3
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, López-Guillermo A, Brito-Zerón P, ; SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus 2004;13:969-71
   PubMed Web of Science ®Google Scholar
• Somer BG, Tsai DE, Downs L, ; American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines. Improvement I Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003;49:394-8
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kalomenidis I, Malagari K, Extranodal marginal zone B-cell lymphoma of the lung in Sjögren's syndrome patients: reappraisal of clinical, radiological, and pathology findings. Respir Med 2007;101:84-92
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R, Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007;179:3351-61
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Moretti M, Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008;2:38-43
   PubMedGoogle Scholar
• Saito Y, Miyagawa Y, Onda K, BAFF inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology 2008;125:570-90
   PubMed Web of Science ®Google Scholar
• Severino ML, Pierangeli D, Ragno A, Efficacy and tolerability of rituximab in secondary Sjögren's syndrome therapy [abstract]. 10th International Symposium on Sjögren's syndrome; 2009. p. 47
   Google Scholar
• Moreno-Guzmán R, Scali JJ. Rituximab: efficacy and safety in patients with primary Sjögren's syndrome [abstract]. 10th International Symposium on Sjögren's Syndrome; 2009. p. 47
   Google Scholar
• Logvinenko OA, Vasilyev VI, Probatova NA, Rituximab in treatment patients with primary Sjögren's syndrome [abstract]. 10th International Symposium on Sjögren's Syndrome; 2009. p. 98
   Google Scholar
• Meijer JM, Meiners PM, Vissink A, Effective rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial [abstract]. 10th International Symposium on Sjögren's Syndrome; 2009. p. 98
   Google Scholar
• Schneider P, MacKay F, Steiner V, BAFF, a novel ligand of the TNF family, stimulates B cell growth. J Exp Med 1999;189:1747-56
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH, Association of BAFF overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68
   PubMed Web of Science ®Google Scholar
• Pers JO, Daridon C, Devauchelle V, BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005;1050:34-9
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, The level of BLyS correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71
   PubMed Web of Science ®Google Scholar
• d'Arbonneau F, Pers JO, Devauchelle V, BAFF-induced changes in BCR-containing lipid rafts in Sjögren's syndrome. Arthritis Rheum 2006;54:115-26
   PubMed Web of Science ®Google Scholar
• Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004;202:237-49
   PubMed Web of Science ®Google Scholar
• Le Pottier L, Bendaoud B, Renaudineau Y, New ELISA for B cell-activating factor. Clin Chem 2009;55:1843-51
   PubMed Web of Science ®Google Scholar
• Seshasayee D, Valdez P, Yan M, Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-88
   PubMed Web of Science ®Google Scholar
• Baker KP, Edwards BM, Main SH, Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
   PubMed Web of Science ®Google Scholar
• Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who's who? Autoimmun Rev 2008;7:267-7
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008;223:156-74
   PubMed Web of Science ®Google Scholar
• García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Use of rituximab in patients with SLE: an update. Autoimmun Rev 2009;8:343-8
   PubMed Web of Science ®Google Scholar